Gemtuzumab ozogamicin

Generic Name
Gemtuzumab ozogamicin
Brand Names
Mylotarg
Drug Type
Biotech
Chemical Formula
-
CAS Number
220578-59-6
Unique Ingredient Identifier
8GZG754X6M
Background

Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody . The antibody ...

Indication

Indicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial tr...

Associated Conditions
Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)
Associated Therapies
-
Clinical Trials
Related News

Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission

First Posted Date
2009-08-20
Last Posted Date
2009-08-20
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Target Recruit Count
168
Registration Number
NCT00962767

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

First Posted Date
2009-05-08
Last Posted Date
2019-05-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
52
Registration Number
NCT00895934
Locations
🇺🇸

Stanford University Hospitals and Clinics, Stanford, California, United States

🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

🇺🇸

University of Washington Medical Center, Seattle, Washington, United States

and more 1 locations

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

First Posted Date
2009-04-16
Last Posted Date
2013-09-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
43
Registration Number
NCT00882102
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

First Posted Date
2008-12-03
Last Posted Date
2024-05-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
270
Registration Number
NCT00801489
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

First Posted Date
2008-11-26
Last Posted Date
2015-02-04
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
29
Registration Number
NCT00798213

Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

First Posted Date
2008-10-03
Last Posted Date
2019-02-18
Lead Sponsor
University of California, San Diego
Target Recruit Count
50
Registration Number
NCT00766116
Locations
🇺🇸

Northside Hospital/BMTGA, Atlanta, Georgia, United States

🇺🇸

UCSD Moores Cancer Center, La Jolla, California, United States

🇺🇸

Stanford University, Stanford, California, United States

Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

First Posted Date
2008-05-07
Last Posted Date
2017-06-01
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
31
Registration Number
NCT00673153
Locations
🇺🇸

Stanford University, Stanford, California, United States

🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 1 locations

Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML

First Posted Date
2008-05-01
Last Posted Date
2015-04-22
Lead Sponsor
New York Medical College
Target Recruit Count
12
Registration Number
NCT00669890
Locations
🇺🇸

Morgan Stanley Children's Hospital of NYP, New York City, New York, United States

Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

First Posted Date
2008-04-17
Last Posted Date
2016-01-15
Lead Sponsor
University of Pittsburgh
Target Recruit Count
5
Registration Number
NCT00660036
Locations
🇺🇸

University of Pittsburgh Cancer Institute / Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

First Posted Date
2008-04-15
Last Posted Date
2024-11-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
133
Registration Number
NCT00658814
Locations
🇺🇸

Salina Regional Health Center, Salina, Kansas, United States

🇺🇸

Saint Ann's Hospital, Westerville, Ohio, United States

🇺🇸

Cancer Center of Kansas - Salina, Salina, Kansas, United States

and more 174 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy